Details of the Drug Combination

General Information of Drug Combination (ID: DCSRGRU)

Drug Combination Name
Paromomycin Pepstatin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Paromomycin   DM1AGXN Pepstatin   DM9S1EA
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 12.65
Bliss Independence Score: 12.65
Loewe Additivity Score: 23.86
LHighest Single Agent (HSA) Score: 23.86

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Paromomycin
Disease Entry ICD 11 Status REF
Amoebiasis 1A36 Approved [2]
Hepatic coma N.A. Approved [2]
Intestinal amebiasis 1A36 Approved [3]
Paromomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [5]
------------------------------------------------------------------------------------
Paromomycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of Pepstatin
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Terminated [4]
Pepstatin Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) TT7EASG Q9N6S8_PLAFA Inhibitor [7]
Plasmodium Plasmepsin 2 (Malaria PLA2) TTXMNHO PLM2_PLAFA Inhibitor [8]
Plasmodium Plasmepsin 1 (Malaria PLA1) TTH9VL3 PLM1_PLAFA Inhibitor [8]
Plasmodium Cysteine protease falcipain (Malaria CPF) TTJNPTK NOUNIPROTAC Inhibitor [8]
------------------------------------------------------------------------------------
Pepstatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cathepsin D (CTSD) OTQZ36F3 CATD_HUMAN Decreases Activity [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Paromomycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004280)
5 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
6 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
7 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
8 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
9 Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ. 2001 May;8(5):477-85. doi: 10.1038/sj.cdd.4400843.